The evidence behind a licensing deal
LinkedIn caption
🤝 The evidence behind a licensing deal
At ARDD 2026, Takeda’s Phil McGurk and AstraZeneca’s Mark Cobbold discussed how promising research becomes a development partnership. McGurk emphasized translational confidence, clear regulatory paths and credible scientific champions.
💡 Cobbold pointed to early in vivo CAR T results that helped drive a rapid acquisition, showing how convincing data can change development plans. The panel also examined licensing structures that share risk through milestones and royalties. For longevity companies, the central question is how to connect compelling biology with evidence a partner can develop into a medicine.
#ARDD2026 #DrugDiscovery
X caption
🤝 Phil McGurk and Mark Cobbold at #ARDD2026: strong biological evidence, clear regulatory paths and scientific champions help turn promising research into development partnerships. Translational confidence matters as much as the promise of an idea.
#DrugDiscovery
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
